Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease

Brain Research

Volumn 968, Issue 2, 2003, Pages 206-218

  Kunikowska, Grazyna ^a   Jenner, Peter ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Neurodeg Diseases Research Centre   (United Kingdom)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Antioxidant enzyme; Basal ganglia; MPTP treated marmoset; Oxidative stress; Parkinson's disease; Primate brain

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; MESSENGER RNA; SINGLE STRANDED DNA; TOXIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN CELL; BRAIN REGION; CELL LOSS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA PROBE; DOPAMINERGIC NERVE CELL; FEMALE; GLIA CELL; GLOBUS PALLIDUS; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; MARMOSET; NEURITE; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

EID: 0037432517     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02240-6     Document Type: Article

References (64)

1. Alam Z.I., Daniel S.E., Lees A.J., Marsden C.D., Jenner P., Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy Body Disease. J. Neurochem. 69:1997;1326-1329.
2. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyquanine levels in substantia nigra. J. Neurochem. 69:1997;1196-1203.
3. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch. Neurol. 32:1975;114-118.
4. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 35:1985;949-956.
5. Bensadoun J.C., Mirochnitchenko O., Inouye M., Aebischer P., Zurn A.D. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Eur. J. Neurosci. 10:1998;3231-3236.
6. Bergeron C., Petrunka C., Weyer L. Copper/zinc superoxide dismutase expression in the human central nervous system. Correlation with selective neuronal vulnerability. Am. J. Pathol. 148:1996;273-279.
7. Burns R.S., LeWitt P.A., Ebert M.H., Pakkenberg H., Kopin I.J. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl. J. Med. 312:1985;1418-1421.
8. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., Parks J.P., Parker W.D., Bennet J.P. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta. 28:1997;77-86.
9. Ceballos I., Lafon M., Javoy-Agid F., Hirsch E.C., Nicole A., Sinet P.M., Agid Y. Superoxide dismutase and Parkinson's disease. Lancet. 335:1990;1035-1036.
10. Chan P.H., Kawase M., Murakami K., F Chen S., Li Y., Calagui B., Reola L., Carlson E., Epstein C.J. Over-expression of SOD1 in transgenic rats protects vulnerable neurons against ischaemic damage after global cerebral ischaemia and reperfusion. J. Neurosci. 18:1998;8292-8299.
11. Damier P., Hirsch E.C., Zhang P., Agid Y., Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 52:1993;1-6.
12. Dexter D., Carter C., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet. 13:1986;639-640.
13. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
14. Dexter D.T., Holley A.E., Flitter W.D., Slatter T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:1994;92-97.
15. Floor E., Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70:1988;268-275.
16. Gnanalingham K.K., Smith L.A., Hunter A.J., Jenner P., Marsden C.D. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse. 1:1993;184-194.
17. Huang J., Philbert M.A. Distribution of glutathione, and glutathione-related enzyme systems in mitochondria and cytosol of cultured cerebellar astrocytes and granular cells. Brain Res. 680:1995;16-22.
18. Jellinger K. The pathology of parkinsonism. Movement Disorders. Vol. 2:1987;125-130 Butterworths.
19. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;161-170.
20. Jenner P.J., Rupniak N.M.J., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50:1984;85-90.
21. Kim-Han J.S., Sun A.Y. Protection of PC12 cells glutathione in L-DOPA induced cytotoxicity. Free Radic. Biol. Med. 25:1998;512-518.
22. Kingsbury A.E., Foster O.J.F., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol. Brain Res. 28:1995;311-318.
23. Kish S.J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease. Neurosci. Lett. 58:1985;343-346.
24. Kish S.J., Morito C.L.H., Hornykiewicz O. Brain glutathione peroxidase in neurodegenerative disorders. Neurochem. Pathol. 4:1986;23-28.
25. Kobayashi K., Kaneda N., Ichinose H., Kishi F., Nakazawa A., Kurosawa Y., Fujika K., Nagatsu T. Isolation of a full-length cDNA clone encoding human tyrosine hydroxylase type 3. Nucl. Acid Res. 15:1987;6733.
26. Kostrzewa M., Damina M.S., Muller U. Superoxide dismutase 1: identification of a novel mutation in a case of familial amyotrophic lateral sclerosis. Hum. Genet. 89:1996;48-50.
27. Kostrzewa R.M., Kostrzewa J.P., Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 23:2002;57-63.
28. Kunikowska G., Gallagher I., Glover V., Clow A., Jenner P. Effects of short- and long-term (-)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain. Brain Res. 953:2002;1-11.
29. Kunikowska G., Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia m-RNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res. 922:2001;51-64.
30. Kunikowska G., Jenner P. The distribution of copper, zinc- and manganese superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia. Biochem. Pharmacol. 63:2002;1159-1164.
31. Ledig M., Fried R., Ziessel M., Mandel P. Regional distribution of superoxide dismutase in rat during post-natal development. Dev. Brain Res. 4:1982;333-337.
32. Lei X.G. Glutathione peroxidase-1 gene knockout on body antioxidant defense in mice. Biofactors. 14:2001;93-99.
33. Liu X.H., Kato H., Araki T., Itoyama Y., Kato K., Kogure K. An immunohistochemical observation of manganese superoxide dismutase in rat substantia nigra after occlusion of middle cerebral artery. Neurosci. Lett. 173:1994;103-106.
34. Loomis T.C., Yees G., Stahl W.L. Regional and subcellular distribution of superoxide dismutase in brain. Experentia. 32:1976;1374-1376.
35. Marttila R.J., Lorentz H., Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86:1988;321-331.
36. Marttila R.J., Viljanen M., Toivonen E., Lorentz H., Rinne U.K. Superoxide dismutase-like activity in the Parkinson's disease brain. Adv. Neurol. 53:1990;141-144.
37. McGeer P.L., Kawamata T., Walker D.G., Akiyama H., Tooyama I., McGeer E.G. Microglia in degenerative neurological disease. Glia. 7:1993;84-92.
38. Mizuno Y., Matsuda S., Yoshino H., Mori H., Hattori N., Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35:1994;204-210.
39. Mizuno Y., Ohta K. Regional distribution of thiobarbituric acid-reactive products, activities of enzymes regulating the metabolism of oxygen free radicals, and some of the related enzymes in adult and aged rat brains. J. Neurochem. 46:1986;1344-1352.
40. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Res. Commun. 163:1989;1450-1455.
41. Mullenbach G.T., Tabrizi A., Irvine B.D., Bell G.I., Hallewell R.A. Sequence of a cDNA coding for human glutathione peroxidase confirms TGA encodes active site selenocysteine. Nucl. Acid Res. 15:1987;5484.
42. Nakamura K., Wright D.A., Wiatr T., Kowlessur D., Milstein S., Lei X.G., Kang U.J. Preferential resistance of dopaminergic neurones to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin. J. Neurochem. 74:2000;2305-2314.
43. O'Callaghan J.P. Quantitative features of reactive gliosis following toxicant-induced damage in the CNS. Ann. N. Y. Acad. Sci. 679:1993;195-210.
44. Pardo C.A., Xu Z., Borchelt D.R., Price D.L., Sisodia S., Cleveland D.W. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc. Natl. Acad. Sci. USA. 92:1994;954-958.
45. Pearce R.K.B., Owen A., Daniel S., Jenner P., Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104:1997;661-677.
46. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310.
47. Poirier J., Dea D., Bacchichet A., Thiffault C. Superoxide dismutase expression in Parkinson's disease. Ann. N. Y. Acad. Sci. 738:1994;116-120.
48. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
49. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., Marsden C.D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697.
50. Schapira A.H.V. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov. Disord. 9:1994;125-138.
51. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
52. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., Marsden C.D. Glutathione-related enzymes in Parkinson's disease. Ann. Neurol. 36:1994;356-361.
53. Snow B.J., Vingerhoets F.J., Langston J.W., Tetrud J.W., Sossi V., Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry. 68:2000;313-316.
54. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
55. Soliman M.K., Mazzio E., Soliman K.F. Levodopa modulating effects of inducible nitric oxide synthase and reactive oxygen species in glioma cells. Life Sci. 72:2002;185-198.
56. Stephan H., Baron G., Schwerdtfeger W.K. The Brain of the Common Marmoset (Callithrx jacchus). A Stereotactic Atlas. 1980;Springer Verlag, Berlin, Heidelberg, New York.
57. Thomas T.N., Priest D.G., Zemp J.W. Distribution of superoxide dismutase in rat brain. J. Neurochem. 27:1976;309-310.
58. Trepanier G., Furling D., Puymirat J., Mirault M.E. Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. Neuroscience. 75:1996;231-243.
59. Van Domberg P.H.M.F., ten Donkelaar H.J. Human SN and VTA: Neuroanatomical Study With Notes On Ageing and Ageing Diseases. 1991;Springer Verlag, Berlin, New York.
60. Waters C.M., Hunt S.P., Jenner P., Marsden C.D. An immunohistochemical study of the acute and long-term effects if 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience. 23:1987;1025-1039.
61. Yoritaka A., Hattori N., Mori H., Kato K., Mizuno Y. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J. Neurol. Sci. 148:1997;181-186.
62. Yoritaka A., Hattori N., Uchida T., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 93:1996;2696-2701.
63. Zhang P., Damier P., Hirsch E.C., Agid Y., Ceballos-Picot I., Sinet P.M., Nicole A., Laurent M., Javoy-Agid F. Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon. Neuroscience. 55:1993;167-175.
64. Zhang J., Graham D.G., Montine T.J., Ho Y.S. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59:2000;53-61.